Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

This study is testing a three-drug combination — zanubrutinib (a targeted therapy), lenalidomide (an immune-modulating drug), and R-ICE (standard salvage chemotherapy) — for patients with diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed to have DLBCL (a type of aggressive blood cancer) that is CD20-positive - Your lymphoma has relapsed or stopped responding after at least one prior treatment - You are in acceptable physical condition (ECOG 0–2) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your blood counts or organ function are critically low - You have untreated brain involvement of lymphoma Talk to your doctor to see if this trial is right for you.